Boston Common Asset Management LLC reduced its stake in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 7.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 339,393 shares of the company's stock after selling 29,160 shares during the quarter. Boston Common Asset Management LLC's holdings in Roche were worth $17,575,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in RHHBY. Sentinel Trust Co. LBA purchased a new stake in Roche during the 3rd quarter worth about $878,000. Vestmark Advisory Solutions Inc. purchased a new position in Roche in the 3rd quarter valued at about $597,000. Altrius Capital Management Inc boosted its stake in shares of Roche by 4.0% during the 3rd quarter. Altrius Capital Management Inc now owns 198,278 shares of the company's stock worth $8,290,000 after purchasing an additional 7,659 shares during the last quarter. Knuff & Co LLC purchased a new stake in shares of Roche during the second quarter worth about $255,000. Finally, Enterprise Financial Services Corp purchased a new stake in shares of Roche during the fourth quarter worth about $270,000.
Roche Stock Performance
OTCMKTS RHHBY opened at $48.84 on Tuesday. Roche Holding AG has a 12 month low of $34.75 and a 12 month high of $60.85. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. The company has a 50-day moving average of $55.10 and a 200-day moving average of $49.67.
Wall Street Analysts Forecast Growth
RHHBY has been the topic of several recent analyst reports. TD Cowen reissued a "hold" rating on shares of Roche in a research note on Tuesday, February 10th. JPMorgan Chase & Co. raised shares of Roche from an "underweight" rating to a "neutral" rating in a research note on Monday, December 8th. HSBC reiterated a "buy" rating and issued a $57.00 price target on shares of Roche in a report on Wednesday, December 10th. The Goldman Sachs Group raised Roche from a "sell" rating to a "hold" rating in a research note on Thursday, January 15th. Finally, Wolfe Research reaffirmed an "outperform" rating on shares of Roche in a research report on Thursday, February 26th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Roche presently has a consensus rating of "Hold" and an average price target of $57.00.
Get Our Latest Report on RHHBY
Roche Company Profile
(
Free Report)
Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.
In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.
See Also
Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holding AG (OTCMKTS:RHHBY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.